PhD Theses

Underneath you can find the PhD theses of our professional PhDs who completed their PhD projects:

• Pieter Stolk (2008) -From new molecules to leads for innovation – studies on the post-innovation learning cycle for pharmaceuticals
• Harald Heemstra (2010) – From research on rare diseases to new orphan drug development
• Marjolein Willemen (2011) – The context of medicines’ use in benefit-risk evaluation
• Hans Ebbers (2011) – Biopharmaceuticals as Challenges to the Regulatory System
• Thijs Giezen (2011) – Risk management of biologicals: a regulatory and clinical perspective
• Brenda Waning (2012) – Innovative approaches for pharmaceutical policy research in developing countries
• Jarno Hoekman (2012) – Science in an age of globalisation: the geography of research collaboration and its effect on scientific publishing
• Alexandra Cameron (2013) – Understanding access to medicines in low and middle-income countries through the use of price and availability indicators
• Michelle Putzeist (2013) – Marketing authorization of new medicines in the EU: towards…
• Giovanni Tafuri (2013) – Exploring the regulatory decision making process for medicines
• Joëlle Hoebert (2013) – Cross-country variation in medicines use; a pharmaceutical system perspective
• Christine Leopold (2014) – Pharmaceutical policy analysis – A European perspective on pricing and reimbursement in challenging times
• Verica Ivanovska (2014) – Pediatric drug formulations: a review of challenges and progress
• Francisco Hernandez (2015) – Subfilter Scale Modelling for Large Eddy Simulation of Lean Hydrogen-Enriched Turbulent Premixed Combustion
• Peter Stephens (2015) – Access to Medicines: Common problems, Common solutions?
• Niels Vermeer (2015) – Pharmacovigilance of biologicals: dynamics in post-approval safety learning
• Luther Gwaza (2016) – Adjusted indirect treatment comparisons of bioequivalence studies
• Sarah Kleijnen (2016) – Harmonising relative effectiveness assessments of medicines in Europe
• Joris Langedijk (2016) – Continuous innovation in the drug life cycle
• Tom Achoki (2016) – Revisiting Health System Performance Assessment in Africa
• Ruben Duijnhoven (2016) – Assessing long-term and rare adverse effects of medicines
• Rianne van den Ham (2016) – Benefits and risks for the individual, anticoagulation for patients with atrial fibrillation
• Yared Santa Ana Telez (2016) – Evaluating pharmaceutical policies using cross-national comparisons and time series analysis
• Yaser Bazerghani (2016) – Access to essential medicines in low and middle income countries
• Daniel Ankrah (2017) – Pharmaceutical policies and access to medicines : a hospital-pharmacy perspective from Ghana
• Sander van den Bogert (2017) – Trials & Tribulations: Studies on the fate, transparency and efficiency of clinical drug trials
• Iga Lipska (2017) – Variation in Health Technology Assessment of new medicines: processes and outcomes
• Evans Sagwa (2017) – Optimizing the Safety of Multidrug-resistant Tuberculosis Therapy in Namibia
• Raymond Tetteh (2018) – The Use and Safety of Antiretroviral Medicines: Lessons from Ghana
• Teresa Alves (2018) – Patient Perspectives in Pharmaceutical Policy: Information and influence in the diffusion of new medicines